Kiniksa Q3 Report, Portfolio Update

 - Q3 2021 ARCALYST® (rilonacept) net revenue of $12.1 million -

- ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval -
- Data from Phase 3 trial of mavrilimumab in COVID-19-related ARDS expected in Q1 2022 -
- Data from Phase 2b trial of vixarelimab in prurigo nodularis expected in 2H 2022 -
- Conference call and webcast scheduled for 8:30 am ET today -

Financial Guidance

• Kiniksa expects ARCALYST net revenue for the fourth quarter of 2021 to be between $16.0 million and $17.0 million.

• Kiniksa continues to expect that its cash, cash equivalents and short-term investments will fund its current operating plan into 2023.

Conference Call Information
Kiniksa will host a conference call and webcast at 8:30 am ET on Monday, November 1, 2021 to discuss third quarter 2021 financial results and to provide a corporate update.

Individuals interested in participating in the call should dial (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1699563. To access the webcast, please visit the Investors and Media section of Kiniksa’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

https://finance.yahoo.com/news/kiniksa-pharmaceuticals-reports-third-quarter-120000891.html